Kafrelsheikh University
🇪🇬Egypt
Early Versus Delayed Laparoscopic Cholecystectomy Following ERCP in Concomitant Gallstones and Common Bile Duct Stones
Not Applicable
Completed
- Conditions
- Choledocholithiasis With Cholecystitis
- Interventions
- Procedure: Laparoscopic cholecystectomy
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 66
- Registration Number
- NCT04475796
- Locations
- 🇪🇬
Kafrelsheikh University, Kafr Ash Shaykh, Kafr Al Sheikh, Egypt
Effect of Platelet Rich Plasma on Healing of Operated Pilonidal Sinus by Open Method
Not Applicable
Completed
- Conditions
- Pilonidal Disease of Natal Cleft
- Interventions
- Biological: Platelet Rich Plasma
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 100
- Registration Number
- NCT04430413
- Locations
- 🇪🇬
Kafr El Sheikh University Hospital, Kafr Ash Shaykh, Kafr El Sheikh Governorate, Egypt
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
Phase 2
- Conditions
- COVID-19
- Interventions
- Other: PlaceboDrug: Aerosolized 13 cis retinoic acidDrug: Aerosolized All trans retinoic acid
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 360
- Registration Number
- NCT04396067
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
Phase 2
- Conditions
- COVID-19
- Interventions
- Drug: Aerosolized Isotretinoin plus Tamoxifen
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 160
- Registration Number
- NCT04389580
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications
Phase 1
- Conditions
- COVID
- Interventions
- Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 24
- Registration Number
- NCT04382950
Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2
Phase 1
- Conditions
- COVID-19
- Interventions
- Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 24
- Registration Number
- NCT04375046
Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients
Phase 1
- Conditions
- COVID-19
- Interventions
- Other: placeboDrug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-06-24
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 56
- Registration Number
- NCT04371822
- Locations
- 🇪🇬
Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt
Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 200
- Registration Number
- NCT04367155
- Locations
- 🇪🇬
Kafrelsheikh faculty of medicine, Kafr Ash Shaykh, Kafrelsheikh, Egypt
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
Phase 3
- Conditions
- COVID19
- Interventions
- Drug: Aerosolized 13 cis retinoic acidDrug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatmentDrug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatmentDrug: Standard treatment
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 100000
- Registration Number
- NCT04353180
- Locations
- 🇪🇬
Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt
Bladder and Prostate Sonomorphology in Patients With Symptomatic Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Radiation: pelvic Ultrasound
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 200
- Registration Number
- NCT04352257
- Locations
- 🇪🇬
Kafrelsheikh faculty of medicine, Kafr Ash Shaykh, Kafrelsheikh, Egypt
© Copyright 2025. All Rights Reserved by MedPath